Ascletis Pharma, Inc. (1672) Stock Statistics & Valuation Metrics

Ascletis Pharma, Inc. has a market cap or net worth of HK$8.17B. The enterprise value is HK$4.80B.

Ascletis Pharma, Inc. has 969,430,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascletis Pharma, Inc.’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -20.40%.

The current PE Ratio of Ascletis Pharma, Inc. is -9.41. Ascletis Pharma, Inc.’s PEG ratio is 2.82.

In the last 12 months, Ascletis Pharma, Inc. had revenue of 1.28M and earned -300.94M in profits. Earnings per share was -0.30.

In the last 12 months, operating cash flow was -203.41M and capital expenditures 0.00, giving a free cash flow of -203.41M billion.

Ascletis Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Ascletis Pharma, Inc. upcoming earnings date is Aug 25, 2025, TBA Not Confirmed.

Ascletis Pharma, Inc. as a current ratio of 12.88, with Debt / Equity ratio of 0.39%

In the past 12 months, Ascletis Pharma, Inc. has paid 0.00 in taxes.

Ascletis Pharma, Inc. EV to EBITDA ratio is -5.05, with an EV/FCF ratio of 0.00.

Ascletis Pharma, Inc. has HK$1.95B in cash and marketable securities with ¥7.63M in debt, giving a net cash position of -HK$1.94B billion.

Gross margin is 57.29%, with operating margin of -31442.17%, and net profit margin of -23455.65%.

The average price target for Ascletis Pharma, Inc. is HK$3.94, which is 11.43% higher than the current price. The consensus rating is Hold